<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">GLIDDON, ANGELA E.</style></author><author><style face="normal" font="default" size="100%">DORÉ, CAROLINE J.</style></author><author><style face="normal" font="default" size="100%">DUNPHY, JULIET</style></author><author><style face="normal" font="default" size="100%">BETTERIDGE, ZOË</style></author><author><style face="normal" font="default" size="100%">McHUGH, NEIL J.</style></author><author><style face="normal" font="default" size="100%">MADDISON, PETER J.</style></author><author><style face="normal" font="default" size="100%">the QUINS Trial Study Group</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Antinuclear Antibodies and Clinical Associations in a British Cohort with Limited Cutaneous Systemic Sclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Rheumatology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">702-705</style></pages><doi><style  face="normal" font="default" size="100%">10.3899/jrheum.100754</style></doi><volume><style face="normal" font="default" size="100%">38</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Objective. To assess the prevalence of disease-specific autoantibodies in patients with limited cutaneous systemic sclerosis (lcSSc). Methods. Sera from 180 patients with lcSSc were analyzed for antinuclear antibody (ANA). Clinical characteristics were compared in the presence or absence of specific autoantibodies. Results. SSc-specific antibodies were detected in 135 patients (75%). Associations were found between anticentromere antibody and age at lcSSc diagnosis, telangiectasia, reduced creatinine clearance, and selective reduction in DLCO, and between antitopoisomerase-I and pulmonary fibrosis. Conclusion. The majority of patients with lcSSc belong to distinctive serologic subsets, potentially with prognostic significance.</style></abstract></record></records></xml>